Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV-16/18 antibodies.

Autor: Rosillon D; GSK, Wavre, Belgium., Baril L; GSK, Wavre, Belgium., Del Rosario-Raymundo MR; Department of Obstetrics and Gynecology, San Pablo Colleges Medical Center, San Pablo City, The Philippines., Wheeler CM; University of New Mexico Health Sciences Center, Albuquerque, New Mexico., Skinner SR; Vaccines Trials Group, Telethon Kids Institute, Perth, Western Australia, Australia.; Sydney University Discipline of Paediatrics and Child Health, Children's Hospital Westmead, Sydney, New South Wales, Australia., Garland SM; The Royal Women's Hospital, The Royal Children's Hospital, Murdoch Childrens Research Institute, University of Melbourne, Parkville, Victoria, Australia., Salmeron J; Instituto Mexicano del Seguro Social, Morelos, Mexico., Lazcano-Ponce E; National Institute of Public Health, Cuernavaca, Mexico., Vallejos CS; Departamento de Oncología Médica, Oncosalud-AUNA, Lima, Peru., Stoney T; Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia., Ter Harmsel B; Department of Gynecology, Roosevelt Kliniek, Leiden, Delft, The Netherlands., Lim TYK; KK Hospital, Singapore City, Singapore., Quek SC; ASC Clinic for Women, Gleneagles Hospital, Singapore City, Singapore., Minkina G; City Clinical Hospital, Moscow, Russia., McNeil SA; Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Nova Scotia, Canada., Bouchard C; Clinique de Recherche en Santé des Femmes, Québec City, Québec, Canada., Fong KL; Singapore General Hospital, Singapore City, Singapore., Money D; The Women's Health Research Institute, University of British Columbia, Vancouver, British Columbia, Canada., Ilancheran A; Division of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, National University Hospital, Singapore City, Singapore., Savicheva A; Laboratory of Microbiology, DO Ott Research Institute of Obstetrics, Gynaecology and Reproductology, St. Petersburg, Russia., Cruickshank M; Department of Obstetrics and Gynaecology, Aberdeen Maternity Hospital, NHS Grampian, Scotland, UK., Chatterjee A; Department of Pediatrics, University of South Dakota Sanford School of Medicine/Sanford Children's Specialty Clinic, Sioux Falls, South Dakota., Fiander A; Leading Safe Choices Programme, Royal College of Obstetricians and Gynaecologists, London, UK., Martens M; Reading Hospital, Pennsylvania., Bozonnat MC; 4Clinics, Paris, France., Struyf F; GSK, Wavre, Belgium., Dubin G; GSK, King of Prussia, Pennsylvania., Castellsagué X; Institut Català d'Oncologia (ICO), IDIBELL, CIBER-ESP, L'Hospitalet de Llobregat, Catalonia, Spain.
Jazyk: angličtina
Zdroj: Cancer medicine [Cancer Med] 2019 Aug; Vol. 8 (10), pp. 4938-4953. Date of Electronic Publication: 2019 Jul 05.
DOI: 10.1002/cam4.1879
Abstrakt: Background: Infections with human papillomavirus (HPV) types 16 and 18 account for ~70% of invasive cervical cancers but the degree of protection from naturally acquired anti-HPV antibodies is uncertain. We examined the risk of HPV infections as defined by HPV DNA detection and cervical abnormalities among women >25 years in the Human Papilloma VIrus Vaccine Immunogenicity ANd Efficacy trial's (VIVIANE, NCT00294047) control arm.
Methods: Serum anti-HPV-16/18 antibodies were determined at baseline and every 12 months in baseline DNA-negative women (N = 2687 for HPV-16 and 2705 for HPV-18) by enzyme-linked immunosorbent assay (ELISA) from blood samples. HPV infections were identified by polymerase chain reaction (PCR) every 6-months, and cervical abnormalities were confirmed by cytology every 12 months. Data were collected over a 7-year period. The association between the risk of type-specific infection and cervical abnormalities and serostatus was assessed using Cox proportional hazard models.
Results: Risk of newly detected HPV-16-associated 6-month persistent infections (PI) (hazard ratio [HR] = 0.56 [95%CI:0.32; 0.99]) and atypical squamous cells of undetermined significance (ASC-US+) (HR = 0.28 [0.12; 0.67]) were significantly lower in baseline seropositive vs baseline seronegative women. HPV-16-associated incident infections (HR = 0.81 [0.56; 1.16]) and 12-month PI (HR = 0.53 [0.24; 1.16]) showed the same trend. A similar trend of lower risk was observed in HPV-18-seropositive vs -seronegative women (HR = 0.95 [0.59; 1.51] for IIs, HR = 0.43 [0.16; 1.13] for 6-month PIs, HR = 0.31 [0.07; 1.36] for 12-month PIs, and HR = 0.61 [0.23; 1.61] for ASC-US+).
Conclusions: Naturally acquired anti-HPV-16 antibodies were associated with a decreased risk of subsequent infection and cervical abnormalities in women >25 years. This possible protection was lower than that previously reported in 15- to 25-year-old women.
(© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje